Skip to main content
. 2017 Aug 29;13:1744806917726256. doi: 10.1177/1744806917726256

Figure 2.

Figure 2.

Treatment with oxaliplatin-induced neuronal hyperexcitability in DRG. (a) Continuous intrathecal delivery of neutralizing antibody against CX3CL1 (10 μg/10 μl for 10 days) attenuates thermal hyperalgesia induced by oxaliplatin (n = 8 in each group; **P < 0.01 versus veh group; #P < 0.05, ##P < 0.01 versus corresponding IgG + oxal group). (b) Representative traces of action potential discharges of DRG neurons acutely dissociated from the vehicle group, the oxaliplatin group, and the anti-CX3CL1 neutralizing antibody + oxaliplatin group. (c) Intrathecal administration of neutralizing antibody against CX3CL1 (10 μg/10 μl for 10 days) significantly inhibited the increase in the AP spikes number of DRG neurons following oxaliplatin treatment (n = 22 in each group; *P < 0.05, **P < 0.01 versus veh group; ##P < 0.01 versus the corresponding oxal group).